ΑΙhub.org
 

Accelerating drug development with AI


by
09 April 2025



share this:

This picture is made up of 9 images in rows of 3. Each row shows a different image of a pill bottle spilling out pills onto a plain surface, on yellow or white backgrounds. On one side, the image is an original photograph. The next two iterations show it getting represented in progressively larger blocks of colour.Rens Dimmendaal & Banjong Raksaphakdee / Medicines (flipped) / Licenced by CC-BY 4.0

Developing new drugs to treat illnesses has typically been a slow and expensive process. However, a team of researchers at the University of Waterloo uses machine learning to speed up the development time.

The Waterloo research team has created “Imagand,” a generative artificial intelligence model that assesses existing information about potential drugs and then suggests their potential properties. Trained on and tested against existing drug data, Imagand successfully predicts important properties of different drugs that have already been independently verified in lab studies, demonstrating the AI’s accuracy.

Traditionally, bringing a successful drug candidate to market can cost between US$2 billion and US$3 billion and take over a decade to complete. Generative AI is posed to transform drug discovery by harnessing large amounts of drug data across diverse areas.

The image from the study shows a correlation between pairs of pharmacokinetic (PK) properties for a single drug. Each drug has its unique chemical profile and set of PK property values. The goal of the diagram is to show the distribution similarity between the real reported pairs of PK properties correlation from in vitro studies and those generated by the researchers’ model. This is important to show that the tool can be helpful in guiding and reducing the cost of large in vitro assays and studies to accelerate pre-clinical drug discovery.

“There’s an enormous pool of possible chemicals and proteins to investigate when developing a new drug, which makes it very expensive to do drug discovery because you have to test millions of molecules with thousands of different targets,” said Bing Hu, a PhD candidate in Computer Science and the lead author on the research. “We are figuring out ways that AI can make that faster and cheaper.”

One of the major challenges in pharmaceutical medicine development is understanding not only how a drug might affect the body in isolation but also how it might interact with other drugs or a person’s lifestyle. This information is particularly difficult to gather because scientific studies of drugs usually only focus on the drugs’ predetermined properties, not on how they may interact with other drugs.

Ultimately, the team hopes medical researchers can use Imagand in the future to understand how drugs interact, allowing them to eliminate potential new drug candidates that would have bad side effects or interactions.

“For example, this AI-enabled process can help us understand how toxic a drug is, how it affects the heart, or how it might interact negatively with other drugs commonly used in treating an illness,” said Helen Chen, a professor in the School of Public Health Sciences and Computer Science at Waterloo. “This is one example of how AI is helping us move towards more precise, personalized care.”

The research, titled “Drug discovery SMILES-to-pharmacokinetics diffusion models with deep molecular understanding“, is currently in preprint.



tags: ,


University of Waterloo




            AIhub is supported by:



Related posts :



Using generative AI, researchers design compounds that can kill drug-resistant bacteria

  05 Sep 2025
The team used two different AI approaches to design novel antibiotics, including one that showed promise against MRSA.

#IJCAI2025 distinguished paper: Combining MORL with restraining bolts to learn normative behaviour

and   04 Sep 2025
The authors introduce a framework for guiding reinforcement learning agents to comply with social, legal, and ethical norms.

How the internet and its bots are sabotaging scientific research

  03 Sep 2025
What most people have failed to fully realise is that internet research has brought along risks of data corruption or impersonation.

#ICML2025 outstanding position paper: Interview with Jaeho Kim on addressing the problems with conference reviewing

  02 Sep 2025
Jaeho argues that the AI conference peer review crisis demands author feedback and reviewer rewards.

Forthcoming machine learning and AI seminars: September 2025 edition

  01 Sep 2025
A list of free-to-attend AI-related seminars that are scheduled to take place between 2 September and 31 October 2025.
monthly digest

AIhub monthly digest: August 2025 – causality and generative modelling, responsible multimodal AI, and IJCAI in Montréal and Guangzhou

  29 Aug 2025
Welcome to our monthly digest, where you can catch up with AI research, events and news from the month past.

Interview with Benyamin Tabarsi: Computing education and generative AI

  28 Aug 2025
Read the latest interview in our series featuring the AAAI/SIGAI Doctoral Consortium participants.

The value of prediction in identifying the worst-off: Interview with Unai Fischer Abaigar

  27 Aug 2025
We hear from the winner of an outstanding paper award at ICML2025.



 

AIhub is supported by:






 












©2025.05 - Association for the Understanding of Artificial Intelligence